Brief: Amneal Receives U.S. FDA Approval Of Sodium Oxybate Oral Solution
11/09/2025 13:20
Sept 11 (Reuters) - Amneal Pharmaceuticals Inc AMRX.O: AMNEAL RECEIVES U.S. FDA APPROVAL OF SODIUM OXYBATE ORAL SOLUTION Source text: ID:nGNX3Bt91c Further company coverage: AMRX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Amneal Pharmaceuticals
See all newsFocus: US progesterone supplies tighten as menopause treatment demand grows
U.S. STOCKS ON THE MOVE-Chipotle Mexican Grill, J.B. Hunt, ABM Industries
U.S. STOCKS ON THE MOVE-G-III Apparel, Amneal Pharmaceuticals, BioCardia
U.S. STOCKS ON THE MOVE-Lululemon, Cooper Companies, Cypherpunk Technologies
Amneal Pharma up after Parkinson’s drug shows benefit in late-stage study